Omron was established by Kazuma Tateishi in 1933 (as the Tateisi Electric Manufacturing Company) and incorporated in 1948. The company originated in an area of Kyoto called "Omuro" from which the name "OMRON" was derived. Prior to 1990, the corporation was known as Omron Tateisi Electronics. During the 1980s and early 1990s, the company motto was: "To the machine the work of machines, to man the thrill of further creation"
Omron High Blood Pressure machine:
Omron's primary business is the manufacture and sale of automation components, equipment and systems, but it is generally known for medical equipment such as digital thermometers, blood pressure monitors and nebulizers. Omron developed the world's first electronic ticket gate which was named an IEEE Milestone in 2007, and was one of the first manufacturers of automated teller machines (ATM) with magnetic stripe card readers.Omron Oilfield & Marine is a provider of AC and DC drive systems and custom control systems for oil and gas and related industries.
Omron was named one of Thomson Reuters Top 100 Global Innovators in 2013.
This file contains additional information such as Exif metadata which may have been added by the digital camera, scanner, or software program used to create or digitize it. If the file has been modified from its original state, some details such as the timestamp may not fully reflect those of the original file. The timestamp is only as accurate as the clock in the camera, and it may be completely wrong.Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation; with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts. A copy of the license is included in the section entitled GNU Free Documentation License
FIB Technology (sometimes referred to as Microlife AFIB Technology) is a feature in sphygmomanometer devices that is designed to detect and monitor the incidence of atrial fibrillation in patients. The technology was designed, patented, and is currently used by the Microlife Corporation. It has been the subject of numerous medical studies and has been validated for in-home and clinical use.[7][8][9][10][11][12] It can be found in several Microlife devices, including the WatchBP Home A, BP A200 Plus, WatchBP Office, and WatchBP O3.[1]
Specifications
Microlife WatchBP Home A blood pressure monitor with Afib detection.
Microlife WatchBP Home A blood pressure monitor with Afib detection.
The Microlife devices that use the AFIB Technology are oscillometric and are equipped with an algorithm that can detect irregular pulse rhythms. The device will flash if atrial fibrillation is detected. Measurements are carried out in triplicate for more accurate readings.[5] Studies have confirmed the relative accuracy of such readings when attempting to identify the existence of atrial fibrillation in patients.
One study indicated that the Microlife blood pressure monitor had a sensitivity for detecting atrial fibrillation of 100%, a specificity of 92%. Several clinical studies have tested the Microlife AFIB Technology against 12-lead electrocardiography (ECG) interpreted by cardiologists. The sensitivity for detection in these studies varied between 95 to 100% with specificity values of 89 to 92%.
Microlife A200 blood pressure monitor with Afib detection.
Microlife A200 blood pressure monitor with Afib detection.
One study noted that the WatchBP device was better for detecting atrial fibrillation than single-lead ECGs because of its higher specificity level (90 vs 76%, respectively), which would prevent many unnecessary refers for a 12-lead ECG and therefore safes labor and healthcare costs. In addition, it does not require clinical interpretation.
In virtually every study, researchers have concluded that Microlife's AFIB Technology is suitable for use as an atrial fibrillation detection system for in-home and/or clinical purposes.[4] In 2013, the UK National Institute for Health and Care Excellence recommended the WatchBP Home A device for routine blood pressure measurement and atrial fibrillation screening in primary care. The recommendation is based on the NICE conclusion that use of WatchBP Home A in primary care is associated with estimated overall cost savings per person measured, ranging from £2.98 for those aged between 65 and 74 years to £4.26 for those aged 75 year
Also Visit ➴
Omron High Blood Pressure machine:
Omron's primary business is the manufacture and sale of automation components, equipment and systems, but it is generally known for medical equipment such as digital thermometers, blood pressure monitors and nebulizers. Omron developed the world's first electronic ticket gate which was named an IEEE Milestone in 2007, and was one of the first manufacturers of automated teller machines (ATM) with magnetic stripe card readers.Omron Oilfield & Marine is a provider of AC and DC drive systems and custom control systems for oil and gas and related industries.
Omron was named one of Thomson Reuters Top 100 Global Innovators in 2013.
This file contains additional information such as Exif metadata which may have been added by the digital camera, scanner, or software program used to create or digitize it. If the file has been modified from its original state, some details such as the timestamp may not fully reflect those of the original file. The timestamp is only as accurate as the clock in the camera, and it may be completely wrong.Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation; with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts. A copy of the license is included in the section entitled GNU Free Documentation License
Also Visit ➴
FIB Technology (sometimes referred to as Microlife AFIB Technology) is a feature in sphygmomanometer devices that is designed to detect and monitor the incidence of atrial fibrillation in patients. The technology was designed, patented, and is currently used by the Microlife Corporation. It has been the subject of numerous medical studies and has been validated for in-home and clinical use.[7][8][9][10][11][12] It can be found in several Microlife devices, including the WatchBP Home A, BP A200 Plus, WatchBP Office, and WatchBP O3.[1]
Also Visit ➴
Specifications
Microlife WatchBP Home A blood pressure monitor with Afib detection.
Microlife WatchBP Home A blood pressure monitor with Afib detection.
The Microlife devices that use the AFIB Technology are oscillometric and are equipped with an algorithm that can detect irregular pulse rhythms. The device will flash if atrial fibrillation is detected. Measurements are carried out in triplicate for more accurate readings.[5] Studies have confirmed the relative accuracy of such readings when attempting to identify the existence of atrial fibrillation in patients.
One study indicated that the Microlife blood pressure monitor had a sensitivity for detecting atrial fibrillation of 100%, a specificity of 92%. Several clinical studies have tested the Microlife AFIB Technology against 12-lead electrocardiography (ECG) interpreted by cardiologists. The sensitivity for detection in these studies varied between 95 to 100% with specificity values of 89 to 92%.
Also Visit ➴
Microlife A200 blood pressure monitor with Afib detection.
Microlife A200 blood pressure monitor with Afib detection.
One study noted that the WatchBP device was better for detecting atrial fibrillation than single-lead ECGs because of its higher specificity level (90 vs 76%, respectively), which would prevent many unnecessary refers for a 12-lead ECG and therefore safes labor and healthcare costs. In addition, it does not require clinical interpretation.
In virtually every study, researchers have concluded that Microlife's AFIB Technology is suitable for use as an atrial fibrillation detection system for in-home and/or clinical purposes.[4] In 2013, the UK National Institute for Health and Care Excellence recommended the WatchBP Home A device for routine blood pressure measurement and atrial fibrillation screening in primary care. The recommendation is based on the NICE conclusion that use of WatchBP Home A in primary care is associated with estimated overall cost savings per person measured, ranging from £2.98 for those aged between 65 and 74 years to £4.26 for those aged 75 year
Also Visit ➴